OC
MACK

Oppenheimer & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Oppenheimer & Co’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,436
Closed -$89K – 1354
2015
Q4 		$89K Buy
+1,436
New +$101K ﹤0.01% 1217
2015
Q3 		– Sell
-6,050
Closed -$589K – 1525
2015
Q2 		$589K Sell
6,050
-5,567
-48% -$530K 0.02% 807
2015
Q1 		$1.09M Sell
11,617
-178
-2% -$15.1K 0.03% 605
2014
Q4 		$1.05M Buy
11,795
+2,377
+25% +$173K 0.03% 589
2014
Q3 		$650K Sell
9,418
-127
-1% -$6.79K 0.02% 760
2014
Q2 		$548K Sell
9,545
-4,594
-32% -$233K 0.02% 825
2014
Q1 		$561K Buy
+14,139
New +$605K 0.02% 784

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Oppenheimer & Co's MACK Position: Q1 2016 in Review

Oppenheimer & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2016, closing a stake of 1,436 shares — an estimated $89K sold.

Oppenheimer & Co first reported a position in MACK in Q1 2014 and held it in 7 quarters. The position peaked at $1.09M in Q1 2015. 139 funds tracked by Wall St. Rank hold MACK as of Q1 2016.

  • Oppenheimer & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Oppenheimer & Co sold 1,436 Merrimack Pharmaceuticals, Inc. shares in Q1 2016, an estimated $89K.
  • Oppenheimer & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2014 and held it in 7 quarters.
  • Oppenheimer & Co's Merrimack Pharmaceuticals, Inc. position peaked at $1.09M in Q1 2015.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2016.

Based on Oppenheimer & Co's 13F filing for Q1 2016, filed 26 Apr 2016.